北京招聘

职位描述：
China Center for mHealth Innovation

The China Center for mHealth Innovation (CCmHI) is a new initiative developed by The George Institute in partnership with Qualcomm Incorporated, through its Wireless Reach? initiative (the Founding Partners). The initiative draws on the Institute’s global experience in the development and evaluation of innovative digital tools to support healthcare providers and consumers in emerging economies, including China. It also draws on Qualcomm Wireless Reach’s broad experience in the design, development and financing of digital healthcare solutions in the US and other established markets (TBC). The CCmHI would be affiliated with Peking University, through The George Institute China, which is a formal affiliate with of the Peking University Health Science Center.

The principal purpose of the CCmHI is to develop, evaluate and implement innovative digital tools to improve the quality of healthcare in China. Such tools provide a particularly powerful means to improve community healthcare, which remains underdeveloped and of highly variable quality. With the rapid expansion of mobile internet connectivity across China, the potential exists for sophisticated clinical decision support systems to provide healthcare workers with evidence-based, personalized guidance about the care of individual patients attending community medical facilities. Such systems can be linked to a range of electronic health records, as well as a range of point-of-care diagnostics. Consumer applications providing tools for self-care can also be provided. Importantly, secure data transfer to a central server enables the quality and outcomes of care to be continuously monitored and managed by regional health authorities. This development would be directly relevant to the Chinese Government’s healthcare reform program, as outlined in China’s 12th Five Year Plan.

The CCmHI has three main initial priorities:

1. To build and evaluate a bespoke digital healthcare platform for use in Chinese primary healthcare settings. In the first instance, the platform would target the management of 10 leading causes of premature death and disability. The initial focus could include urban centers (particularly Beijing), as well as rural areas in which The George has existing operations. The platform would include provider components, consumer support tools, as well others (such as quality control) designed for health care authorities. A landscape analysis of digital health policies, laws, standards, programs and research activities in China will be done to inform the platform development based on The George’s SMART Health platform with appropriate modifications for use in China.

2. To build Chinese capacity in digital healthcare development and evaluation. This would include opportunities for student internships and fellowships. It could also include the eventual development of a Peking University-based Master program and/or executive education program in digital healthcare. Additionally, possibilities exist for the enrolment of exceptional graduates in doctoral research programs at Peking University, the University of Sydney or the University of Oxford (three universities with which The George Institute has formal affiliations).

3. To advocate through appropriate channels for the incorporation of mobile health strategies in Chinese national policies and guidelines. In parallel with its research program, the CCmHI will develop a policy and advocacy program aimed at supporting integration and scale-up of effective affordable digital healthcare technologies. This would include social media programs, as well as direct engagement with stakeholders including government, professional societies and the corporate sector. It could also include workshops on recent developments in digital health for Chinese government officials and other key stakeholders. For the past five years, The George Institute China has run workshops for the National Health and Family Planning Commission (previously the Ministry of Health) on a range of key topics relevant to healthcare policy. These workshops could be extended to include officials from other relevant ministries and commissions such as those responsible for technology, communications and the financing of healthcare.


The role

The successful appointee will support the CCmHI director to build and evaluate the digital healthcare platform to deal with the leading 10 health problems in China. Specific responsibilities include literature review, stakeholder communication, platform structure analysis, function module description, drafting algorithm in plain language, accuracy test together with software engineer, pilot test among users, study design and implementation of scaled clinical trials. The appointee will also take part in potential digital healthcare capacity development and advocacy program, and will be expected to contribute to publications, media reports and other outputs related to mHealth in China and internationally.

The appointee would report to the director of CCmHI and would receive academic and technical supervision from relevant George Institute and university faculty.

Essential

Master’s or higher degree in medicine or biomedical engineering.
Excellent English and Mandarin - both oral and written communication skills.
Competence with computer programs (especially MS Office; MS Word, MS Excel) and electronic communication (email and internet).
Great enthusiasm in digital or mobile health
Excellent communication (written and verbal) and negotiation skills

To apply

Send a CV, focusing on research background, in English and Chinese, to HR_China@georgeinstitute.org.cn & dzhang@georgeinstitute.org.cn with the subject of “RF Application to CCmHI”_ 举报 分享

The George Institute China is a medical research institute, and a wholly-owned foreign enterprise, that was established as an affiliated partner with Peking University Health Science Centre in March 2007, whose registered name is Beijing George Medical Research Co. Ltd. The aim of the Institute is to promote high quality medical research through the conduct of randomised controlled trials and epidemiological studies with various government and non-government partners for the purpose of providing evidence-based approaches to improve the health of Chinese people.
George Clinical is the clinical research delivery arm of the George Institute and manages phase I to phase IV clinical studies for both commercial and medical research organisations. George Clinical is recognized as a leading Clinical Research Organisation (CRO) bringing together medical and scientific expertise in the clinical trials area. George Clinical China is a wholly owned foreign enterprise and trades under the name George (Beijing) Clinical Research Co. Ltd.